Chemed Performance degli utili passati
Criteri Il passato verificati 2/6
Gli utili di Chemed sono diminuiti a un tasso medio annuo di -0.6%, mentre il settore Healthcare ha visto gli utili crescere a un tasso medio annuo di 4%. I ricavi sono cresciuti crescere a un tasso medio annuo di 4.4%. Il ritorno sul capitale proprio di Chemed è 30.6% e ha margini netti di 10.2%.
Informazioni chiave
-0.55%
Tasso di crescita degli utili
1.26%
Tasso di crescita dell'EPS
| Healthcare Crescita del settore | 8.50% |
| Tasso di crescita dei ricavi | 4.42% |
| Rendimento del capitale proprio | 30.64% |
| Margine netto | 10.23% |
| Ultimo aggiornamento sugli utili | 31 Mar 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Aggiornamento della narrazione • Jun 15
CHE: Share Repurchases And Stable Margins Will Support Balanced Future Returns
Analysts have kept their Chemed price target essentially unchanged at about $446.50, with only minimal tweaks to underlying assumptions such as revenue growth, profit margin, and future P/E to reflect updated modeling rather than a shift in overall outlook. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares, representing 3.65% of its stock, for US$197.7 million under its ongoing buyback program.Aggiornamento della narrazione • Jun 01
CHE: Ongoing Buybacks And Stable Margins Will Support Balanced Future Returns
Analysts have nudged their price target on Chemed higher to $446.50 from $443, reflecting updated assumptions around slightly stronger revenue growth, a modestly higher discount rate, stable profit margins, and a lower future P/E multiple. What's in the News Chemed reported that from January 1, 2026 to March 31, 2026, it repurchased 500,000 shares, representing 3.65% of its stock, for US$197.7 million under its ongoing buyback program.Aggiornamento della narrazione • Apr 27
CHE: Ongoing Buybacks And Earnings Guidance Will Support Balanced Future Returns
Analysts now see Chemed’s fair value holding at $443, with updated assumptions for revenue growth of 6.52%, a profit margin of 12.54%, and a future P/E of 15.49x shaping their refreshed price target rationale. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares for $197.7 million, representing 3.65% of its shares under the long running buyback program announced in February 2011 (Key Developments).Aggiornamento della narrazione • Apr 10
CHE: Expanded Buybacks And Earnings Guidance Will Support Stronger Future Returns
Analysts have kept their price target for Chemed steady at $443. This reflects updated assumptions around slightly different revenue growth, profit margin and future P/E inputs that do not materially change their overall valuation view.Aggiornamento della narrazione • Mar 27
CHE: Expanded Buybacks And Higher Margins Will Support Stronger Future Returns
Analysts have maintained Chemed's price target at $443, citing updated assumptions for profit margin and forward P/E as key factors behind the reaffirmed view. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, with projected earnings per diluted share in a range of $23.25 to $24.25, excluding certain non cash items such as stock option expenses, tax benefits from stock option exercises, litigation costs and other discrete items (corporate guidance).Aggiornamento della narrazione • Mar 10
CHE: Revised Outlook And Ongoing Buybacks Will Shape Balanced Future Returns
Analysts have revised their price target on Chemed to $443.00 from $555.50, reflecting updated views on revenue growth, profit margins, and the P/E multiple they consider appropriate for the stock. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, projecting earnings per diluted share, excluding specified non cash and discrete items, in a range of $23.25 to $24.25 (company guidance).
Nuova narrazione • Feb 27
Repositioned Hospice Mix And Aging Demographics Will Support Stronger Long Term Performance
Catalysts About Chemed Chemed operates VITAS Healthcare, a large hospice provider, and Roto-Rooter, a national plumbing and water restoration service business. What are the underlying business or industry changes driving this perspective?Aggiornamento della narrazione • Feb 24
CHE: Stable Margins And Expanded Buybacks Will Support Future Upside
Analysts maintained Chemed's price target at $555.50, citing unchanged views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News On February 13, 2026, Chemed increased its equity buyback authorization by US$300 million to a total of US$3.05 billion under its existing repurchase program (Key Developments).Aggiornamento della narrazione • Feb 10
CHE: Stable Margins And Consistent Assumptions Will Support Future Upside
Analysts have maintained their fair value estimate for Chemed at US$555.50 per share, with only small adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, resulting in a marginally updated price target narrative. Valuation Changes Fair Value: Kept unchanged at US$555.50 per share, indicating no revision to the central valuation output.Aggiornamento della narrazione • Jan 23
CHE: Share Buybacks And Margin Outlook Will Support Future Upside
Analysts now see Chemed's fair value at US$555.50, down from US$582.25. This reflects updated views on the discount rate, revenue growth, profit margin and future P/E assumptions.Articolo di analisi • Jan 16
Here's What Chemed's (NYSE:CHE) Strong Returns On Capital Mean
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Articolo di analisi • Oct 31
Analysts Are Updating Their Chemed Corporation (NYSE:CHE) Estimates After Its Third-Quarter Results
It's been a good week for Chemed Corporation ( NYSE:CHE ) shareholders, because the company has just released its...Articolo di analisi • Oct 24
Chemed Corporation (NYSE:CHE) Shares Could Be 38% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Chemed fair value estimate is US$707 Chemed is estimated to be...Seeking Alpha • Oct 06
Chemed Corp: Genius Of The Model Lies In Its Corporate Strategy
Summary Chemed Corp's unconventional structure is masterfully managed with a disciplined focus on operational excellence and shareholder-friendly capital allocation. The company's primary competitive advantage is its brand, a powerful intangible asset cultivated over nearly a century of reliable service and effective marketing. Chemed has constructed a uniquely durable enterprise built to create shareholder value for the long term. Read the full article on Seeking AlphaAggiornamento della narrazione • Sep 03
New Florida CON Sites Will Advance Home-Based And Hospice Care
Chemed’s modest price target increase to $582.25 reflects stable sentiment, as core metrics like future P/E and revenue growth remain virtually unchanged. What's in the News Increased equity buyback authorization by $300 million, bringing total to $2.75 billion.Articolo di analisi • Jul 07
Chemed Corporation (NYSE:CHE) Shares Could Be 23% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Chemed fair value estimate is US$614 Chemed's US$473 share...
Nuova narrazione • Aug 25
Strategic Acquisitions And Operational Efficiencies Set To Propel VITAS And Roto-Rooter Forward
Strategic acquisitions, such as Covenant Health, and aggressive hiring in VITAS are poised to enhance Chemed's revenue and net margins through improved operational efficiency.Seeking Alpha • Aug 16
Chemed Remains A Buy On Long-Term Economics
Summary Chemed continues to present with exceptional economic characteristics now at depressed valuations vs. history. The business is highly profitable and earns high rates of return on all the capital that's been employed into its operations. Management has an extensive reinvestment runway to redeploy surplus funds and grow the intrinsic worth of the business. Read the full article on Seeking AlphaRipartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Chemed guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Mar 26 | 2,541 | 260 | 423 | 0 |
| 31 Dec 25 | 2,530 | 265 | 414 | 0 |
| 30 Sep 25 | 2,531 | 279 | 416 | 0 |
| 30 Jun 25 | 2,512 | 290 | 407 | 0 |
| 31 Mar 25 | 2,489 | 309 | 414 | 0 |
| 31 Dec 24 | 2,431 | 302 | 419 | 0 |
| 30 Sep 24 | 2,377 | 302 | 415 | 0 |
| 30 Jun 24 | 2,336 | 301 | 418 | 0 |
| 31 Mar 24 | 2,293 | 283 | 406 | 0 |
| 31 Dec 23 | 2,264 | 273 | 395 | 0 |
| 30 Sep 23 | 2,225 | 245 | 392 | 0 |
| 30 Jun 23 | 2,187 | 226 | 376 | 0 |
| 31 Mar 23 | 2,165 | 240 | 369 | 0 |
| 31 Dec 22 | 2,135 | 250 | 359 | 0 |
| 30 Sep 22 | 2,129 | 262 | 354 | 0 |
| 30 Jun 22 | 2,141 | 277 | 359 | 0 |
| 31 Mar 22 | 2,142 | 267 | 365 | 0 |
| 31 Dec 21 | 2,139 | 269 | 367 | 0 |
| 30 Sep 21 | 2,132 | 308 | 361 | 0 |
| 30 Jun 21 | 2,121 | 303 | 361 | 0 |
| 31 Mar 21 | 2,091 | 329 | 351 | 0 |
| 31 Dec 20 | 2,080 | 319 | 330 | 0 |
| 30 Sep 20 | 2,069 | 271 | 322 | 0 |
| 30 Jun 20 | 2,021 | 263 | 311 | 0 |
| 31 Mar 20 | 1,992 | 231 | 298 | 0 |
| 31 Dec 19 | 1,939 | 220 | 306 | 0 |
| 30 Sep 19 | 1,874 | 209 | 289 | 0 |
| 30 Jun 19 | 1,837 | 201 | 279 | 0 |
| 31 Mar 19 | 1,806 | 205 | 276 | 0 |
| 31 Dec 18 | 1,783 | 206 | 271 | 0 |
| 30 Sep 18 | 1,753 | 206 | 276 | 0 |
| 30 Jun 18 | 1,727 | 190 | 275 | 0 |
| 31 Mar 18 | 1,700 | 113 | 271 | 0 |
| 31 Dec 17 | 1,667 | 98 | 271 | 0 |
| 30 Sep 17 | 1,642 | 76 | 261 | 0 |
| 30 Jun 17 | 1,617 | 67 | 254 | 0 |
| 31 Mar 17 | 1,592 | 114 | 249 | 0 |
| 31 Dec 16 | 1,577 | 109 | 238 | 0 |
| 30 Sep 16 | 1,572 | 106 | 240 | 0 |
| 30 Jun 16 | 1,566 | 108 | 234 | 0 |
| 31 Mar 16 | 1,557 | 111 | 233 | 0 |
| 31 Dec 15 | 1,543 | 110 | 233 | 0 |
| 30 Sep 15 | 1,524 | 110 | 229 | 0 |
| 30 Jun 15 | 1,496 | 106 | 229 | 0 |
Guadagni di qualità: CHE ha guadagni di alta qualità.
Margine di profitto in crescita: Gli attuali margini di profitto netti di CHE (10.2%) sono inferiori rispetto allo scorso anno (12.4%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: Gli utili di CHE sono diminuiti del 0.6% all'anno negli ultimi 5 anni.
Accelerare la crescita: CHE ha avuto una crescita negativa degli utili nell'ultimo anno, quindi non può essere confrontata con la sua media quinquennale.
Guadagni vs Settore: CHE ha avuto una crescita negativa degli utili ( -15.9% ) nell'ultimo anno, rendendo difficile il confronto con la media del settore Healthcare ( 17% ).
Rendimento del capitale proprio
ROE elevato: Il Return on Equity ( 30.6% ) di CHE è considerato alto.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/23 22:57 |
| Prezzo dell'azione a fine giornata | 2026/06/23 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Chemed Corporation è coperta da 10 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Adam Feinstein | Barclays |
| Joanna Sylvia Gajuk | BofA Global Research |
| Peter Martin | Citizens JMP Securities, LLC |